



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Evidence-Based Criteria must be read in its entirety to determine coverage eligibility, if any.

This Evidence-Based Criteria provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Evidence-Based Criteria are subject to change as new information becomes available.

For purposes of this Evidence-Based Criteria, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

Description:

Parenteral Nutrition:

Parenteral nutrition is the intravenous administration of nutrition. Parenteral nutrition, also referred to as hyperalimentation, may be total parenteral nutrition (TPN) or supplemental.

- Total parenteral nutrition (TPN): Intravenous feeding that provides all of the carbohydrates, proteins, fats, water, electrolytes, vitamins, and minerals needed for the building of tissue, expenditure of energy, and other physiologic activities. Administration of the nutrients is usually performed through a central venous catheter inserted in the superior vena cava. TPN is used when medical or surgical conditions impair gastrointestinal (GI) absorption causing risk for malnutrition and/or wasting.
- Intradialytic parenteral nutrition (IDPN): Infusion of nutrients during dialysis to treat protein calorie malnutrition for individuals with renal failure. Intravenous administration is performed during hemodialysis through the dialysis tubing. In peritoneal dialysis, also referred to as intraperitoneal parenteral nutrition (IPPN) or intraperitoneal nutrition (IP), nutrition is infused into the peritoneal cavity.

Enteral Nutrition (EN):

Feeding provided through the gastrointestinal tract via a tube (e.g. nasogastric, gastrostomy or jejunostomy tubes), catheter, or stoma that delivers nutrients distal to the oral cavity on a continuous or intermittent schedule. EN is used for individuals with a functioning gastrointestinal (GI) tract who are at risk for malnutrition and/or wasting as the result of disorders of the pharynx, esophagus or stomach that prevent nutrients from reaching the absorbing surfaces of the small bowel.

Criteria:

Total Parenteral Nutrition:

- Initial course of TPN for seven (7) days is considered **medically necessary** with documentation of **ALL**¹ of the following:
 1. Non-functioning GI tract, impaired gastrointestinal (GI) absorption or need for bowel rest as the result of **ONE** of the following medical or surgical conditions, to include, *but not limited to*:
 - Dysphagia as a result of a central nervous system (CNS) disorder with high risk for aspiration
 - Enterocolic, enterovesical, or enterocutaneous fistulas (TPN is considered temporary until the fistula is repaired)
 - Failure to thrive due to systemic disease or secondarily to intestinal insufficiency associated with short bowel syndrome, malabsorption, or chronic idiopathic diarrhea in infants and young children
 - Gastrointestinal anomalies that are catastrophic, e.g., tracheoesophageal fistula, gastroschisis, omphalocele, or massive intestinal atresia in newborn infants

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

- Hypermetabolic conditions:
 - Burns
 - Major surgery
 - Sepsis
 - Trauma
 - Inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis
 - Malnutrition from inadequate oral intake, severe (e.g., chemotherapy-induced nausea and vomiting)
 - Motility disorder (pseudo-obstruction)
 - Necrotizing pancreatitis, severe
 - Neurological impairment
 - Obstruction secondary to stricture or neoplasm of the esophagus or stomach
 - Paralytic ileus for a prolonged period of time following a major surgical procedure or following multiple injuries
 - Perioperative: NPO status (withholding of food and water) for 7 – 14 days *before or after* surgery
 - Pregnancy – hyperemesis and low weight gain from impaired intake or absorption
 - Short bowel syndrome secondary to massive small bowel resection
2. Risk of wasting as documented by the following:
- Weight is significantly less than normal body weight for an individual's height and age in comparison with pre-illness weight, **and**
 - Serum albumin less than 3.2gm, **or**
 - Protein intake less than 0.8g/kg/day
3. Efforts to correct malnutrition have failed, to include, *but not limited to*:
- Treatment of an underlying medical, psychiatric, psychosocial and/or surgical disorder that may be impairing food intake
 - Dietary adjustments and oral supplements
 - Trial of enteral nutrition (tube feeding, G-Tube, J-Tube) has failed or is contraindicated as a result of a medical or surgical condition
4. Individual is unable to orally receive more than 30% of daily caloric needs

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

- Continuation of TPN for an additional seven (7) days is considered **medically necessary** with documentation of **ONE** of the following:
 1. Individual remains at risk of wasting as documented by the following:
 - Weight continues to be significantly less than normal body weight for an individual's height and age in comparison with pre-illness weight, **and**
 - Serum albumin less than 3.2gm **or**
 - Protein intake less than 0.8g/kg/day
 2. Individual continues to need bowel rest

Intradialytic Parenteral Nutrition:

- Initial course of IDPN is considered **medically necessary** with documentation of **ALL** of the following:
 1. Individual is on dialysis
 2. Risk of wasting as documented by the following:
 - Weight is significantly less than normal body weight for an individual's height and age in comparison with pre-illness weight, **and**
 - Serum albumin less than 3.2gm, **or**
 - Protein intake less than 0.8g/kg/day
 3. Efforts to correct malnutrition have failed, to include, *but not limited to*:
 - Treatment of an underlying medical, psychiatric, psychosocial and/or surgical disorder that may be impairing food intake
 - Dietary adjustments and oral supplements
 - Trial of enteral nutrition has failed or is contraindicated as a result of a medical or surgical condition

Enteral Nutrition (EN):

- Initial course of EN for fourteen (14) days is considered **medically necessary** with documentation of **ALL** of the following:
 1. Functional intestinal tract
 2. Inability to swallow as the result of **ONE** of the following medical conditions, to include, *but not limited to*:
 - Anatomical or structural problems or diseases/conditions of the esophagus, including severe allergic reaction, that prevents food from reaching the stomach or other intestinal structures

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

- Neurological disorder resulting in chewing and/or swallowing problem(s) that create a high risk for aspiration
- 3. EN is intended to be the sole source of nutrition²
- 4. The requested nutritional product is not over-the-counter (OTC).
- Continuation of EN in thirty (30) day increments is considered **medically necessary** with documentation that an individual remains unable to orally receive more than 30% of daily caloric needs.
- Continuation of EN for ninety (90) days or greater, not to exceed 365 day increments, is considered **medically necessary** with documentation that EN therapy is chronic and is medically necessary as the sole source of nutrition².
- Initial and continuing 365 day increments of EN for the following indications are considered **medically necessary** and may be approved at the R.N. level of review without the 14, 30, and 90 day increments needing to be met with documentation that EN therapy is chronic and is medically necessary as the sole source of nutrition².

These indications include, *but are not limited to*:

- Amyotrophic Lateral Sclerosis with feeding tube due to probability of aspiration pneumonia
- Persistent aspiration pneumonia
- Enteral Nutrition prescribed as the sole source of nutrition for the treatment of inherited metabolic disorders tested under the state's newborn screening program is **eligible for coverage** under the Medical Food benefit.

¹ Guidelines 2 through 4 do not apply to an individual in need of **bowel rest only**.

² Sole source of nutrition is defined as inability to orally receive more than 30% of daily caloric needs.

Resources:

Literature reviewed 10/17/23. We do not include marketing materials, poster boards and non-published literature in our review.

1. Anderson J., Peterson K., Bourne D, Boundy E. Evidence Brief: Use of Intradialytic Parenteral Nutrition (IDPN) to Treat Malnutrition in Hemodialysis Patients. VA ESP Project #09-199. 2018. Accessed April 2, 2023. <https://www.hsrd.research.va.gov/publications/esp/idpn-supplemental.pdf>
2. Ariz Rev. Stat § 20-2327. (2023)
3. Ariz Rev. Stat § 36-694. (2023)

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

4. Bechtold ML, Brown PM, Escuro A, et al. When is enteral nutrition indicated? *JPEN J Parenter Enteral Nutr.* Sep 2022;46(7):1470-1496. doi:10.1002/jpen.2364
5. Beddhu S, Cho ME, Bansal S. Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis. In: Schwab SJ, ed. *UpToDate.* UpToDate; 2023. Accessed September 7, 2023. <https://www.uptodate.com/contents/pathogenesis-and-treatment-of-malnutrition-in-patients-on-maintenance-hemodialysis>
6. Boullata JI, Carrera AL, Harvey L, et al. ASPEN Safe Practices for Enteral Nutrition Therapy. *JPEN J Parenter Enteral Nutr.* Jan 2017;41(1):15-103. doi:10.1177/0148607116673053
7. Brown RO, Compher C, American Society for P, Enteral Nutrition Board of D. A.S.P.E.N. clinical guidelines: nutrition support in adult acute and chronic renal failure. *JPEN J Parenter Enteral Nutr.* Jul-Aug 2010;34(4):366-77. doi:10.1177/0148607110374577
8. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. *Journal of the American Society of Nephrology : JASN.* Sep 2007;18(9):2583-91. doi:10.1681/ASN.2007020184
9. Capelli JP, Kushner H, Camiscioli TC, Chen SM, Torres MA. Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. *Am J Kidney Dis.* Jun 1994;23(6):808-16. doi:10.1016/s0272-6386(12)80134-x
10. Department of Health and Human Services. Health Care Financing Administration. HCFA Rulings. Ruling No. 96-3. 1996. Accessed April 2, 2023. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Rulings/downloads/hcfa963.pdf>
11. Hiroshige K, Iwamoto M, Kabashima N, Mutoh Y, Yuu K, Ohtani A. Prolonged use of intradialysis parenteral nutrition in elderly malnourished chronic haemodialysis patients. *Nephrol Dial Transplant.* Aug 1998;13(8):2081-7. doi:10.1093/ndt/13.8.2081
12. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. *Am J Kidney Dis.* Sep 2020;76 (3 Suppl 1):S1-S107. doi:10.1053/j.ajkd.2020.05.006
13. Joannidis M, Rauchenzauner M, Leiner B, et al. Effect of intradialytic parenteral nutrition in patients with malnutrition-inflammation complex syndrome on body weight, inflammation, serum lipids and adipocytokines: results from a pilot study. *Eur J Clin Nutr.* Jun 2008;62(6):789-95. doi:10.1038/sj.ejcn.1602777
14. KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. *Am J Kidney Dis.* Mar 2009;53(3 Suppl 2):S11-104. doi:10.1053/j.ajkd.2008.11.017



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: MEDICINE**

**ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

15. Kopple JD, Foulks CJ, Piraino B, Beto JA, Goldstein J. Proposed Health Care Financing Administration guidelines for reimbursement of enteral and parenteral nutrition. *Am J Kidney Dis*. Dec 1995;26(6):995-7. doi:10.1016/0272-6386(95)90066-7
16. Kopple JD. The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients. *Am J Kidney Dis*. Oct 2001;38(4 Suppl 1):S68-73. doi:10.1053/ajkd.2001.27578
17. Liu Y, Xiao X, Qin DP, et al. Comparison of Intradialytic Parenteral Nutrition with Glucose or Amino Acid Mixtures in Maintenance Hemodialysis Patients. *Nutrients*. Jun 2 2016;8(6)doi:10.3390/nu8060220
18. Mueller C, Compher C, Ellen DM, American Society for P, Enteral Nutrition Board of D. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults. *JPEN J Parenter Enteral Nutr*. Jan 2011;35(1):16-24. doi:10.1177/0148607110389335
19. Oguz Y, Bulucu F, Vural A. Oral and parenteral essential amino acid therapy in malnourished hemodialysis patients. *Nephron*. Oct 2001;89(2):224-7. doi:10.1159/000046072
20. Thabet AF, Moeen SM, Labiqe MO, Saleh MA. Could intradialytic nutrition improve refractory anaemia in patients undergoing haemodialysis? *J Ren Care*. Sep 2017;43(3):183-191. doi:10.1111/jorc.12206
21. Toigo G, Situlin R, Tamaro G, et al. Effect of intravenous supplementation of a new essential amino acid formulation in hemodialysis patients. *Kidney Int Suppl*. Nov 1989;27:S278-81.
22. Worthington P, Balint J, Bechtold M, et al. When Is Parenteral Nutrition Appropriate? *JPEN J Parenter Enteral Nutr*. Mar 2017;41(3):324-377. doi:10.1177/0148607117695251

Coding:

HCPCS: B4034, B4035, B4036, B4081, B4082, B4083, B4087, B4088, B4102, B4103, B4104, B4149, B4150, B4152, B4153, B4154, B4155, B4157, B4158, B4159, B4160, B4161, B4162, B4164, B4168, B4172, B4176, B4178, B4180, B4185, B4189, B4193, B4197, B4199, B4216, B4220, B4222, B4224, B5000, B5100, B5200, B9998, B9999

CPT copyright 2023 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: MEDICINE**

**ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

<u>History:</u>	<u>Date:</u>	<u>Activity:</u>
Medical Policy Panel	10/15/24	Review with no revisions
Pediatric Subspecialty Advisory Sub-Committee	05/16/24	Review with revisions
Medical Policy Panel	10/17/23	Approved guideline
Medical Director (Dr. Raja) Clinical Pharmacist	10/06/23	Development
Legal Division	09/15/23	Development

Policy Revisions:



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 11/01/23
LAST REVIEW DATE: 10/15/24
CURRENT EFFECTIVE DATE: 10/15/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PARENTERAL AND ENTERAL NUTRITION

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nilinígíí Blue Cross Blue Shield of Arizona haada yit'éego bina'idílkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yina'idílkidgo beehaz'ánii hólgo díí t'áá hazaadk'ehjí háká a'doowotgo bee haz'á doo baqah ilinígóó. Ata' halne'ígíí kojí' bich'í' hodílnih 877-475-4799.

Chinese: 如果您，或是您正在協助的對象，有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題，您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員，請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:

إن كان لديك أو لدى شخص تساعد أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون أية تكلفة. للتحدث مع مترجم اتصل بـ 877-475-4799.

